Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has updated its full-year 2021 financial guidance to incorporate the GW Pharmaceuticals business, which the company acquired on May...
Investing.com - GW Pharma (NASDAQ:GWPH) ADR reported on Monday first quarter earnings that missed analysts' forecasts and revenue that fell short of expectations. GW Pharma ADR...
The latest deal creating a buzz in the cannabis industry is the US$7.2-billion takeover of GW Pharma (NASDAQ:GWPH) by a little-known, Ireland-based company—Jazz...
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company is also focused on developing its pharmaceutical product pipelines, which includes Epidiolex for the treatment of Tuberous Sclerosis Complex and RETT Syndrome.